SOUTH SAN FRANCISCO, CA -- (Marketwire) -- 06/02/09 -- Theravance, Inc. (NASDAQ: THRX)
announced today that Michael W. Aguiar, Senior Vice President and Chief
Financial Officer, is scheduled to present at the following investor
conferences in June 2009:
Goldman Sachs 30th Annual Global Healthcare Conference
Grand Hyatt, New York, New York
Tuesday, June 9, 2009
11:55 a.m. ET
8th Annual Needham Life Sciences Conference
The New York Palace Hotel, New York, New York
Wednesday, June 10, 2009
8:00 a.m. ET
All webcast information will be available on Theravance's web site at
www.theravance.com. Listeners are encouraged to visit the site at least 15
minutes prior to the scheduled presentation to register, download and
install any necessary audio software.
About Theravance
Theravance is a biopharmaceutical company with a pipeline of internally
discovered product candidates. Theravance is focused on the discovery,
development and commercialization of small molecule medicines across a
number of therapeutic areas including respiratory disease, bacterial
infections and gastrointestinal motility dysfunction. The company's key
programs include: telavancin for the treatment of serious Gram-positive
bacterial infections with Astellas Pharma Inc. and the Horizon program and
Bifunctional Muscarinic Antagonist-Beta2 Agonist (MABA) program with
GlaxoSmithKline plc. By leveraging its proprietary insight of multivalency
toward drug discovery focused primarily on validated targets, Theravance is
pursuing a next generation strategy designed to discover superior medicines
in areas of significant unmet medical need. For more information, please
visit the company's web site at www.theravance.com.
THERAVANCE®, the Theravance logo, and MEDICINES THAT MAKE A DIFFERENCE®
are registered trademarks of Theravance, Inc.
Theravance's presentations will contain certain "forward-looking"
statements as that term is defined in the Private Securities Litigation
Reform Act of 1995 regarding, among other things, statements relating to
goals, plans, objectives and future events. Theravance intends such
forward-looking statements to be covered by the safe harbor provisions for
forward-looking statements contained in Section 21E of the Exchange Act and
the Private Securities Litigation Reform Act of 1995.
